• Cell Cure Neurosciences Ltd., of Jerusalem, a subsidiary of BioTime Inc., received a grant of NIS5.04 million (US$1.33 million) from Israel's Office of the Chief Scientist for development of a cell-based therapeutic product for age-related macular degeneration.